Impax Laboratories Earnings: Here’s Why Investors are Not Happy Now

Impax Laboratories Inc. (NASDAQ:IPXL) delivered a profit and beat Wall Street’s expectations, AND beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company. Shares are down 0.33%.

Impax Laboratories Inc. Earnings Cheat Sheet

Results: Adjusted Earnings Per Share decreased 61.67% to $0.23 in the quarter versus EPS of $0.60 in the year-earlier quarter.

Revenue: Decreased 22.14% to $129.6 million from the year-earlier quarter.

Actual vs. Wall St. Expectations: Impax Laboratories Inc. reported adjusted EPS income of $0.23 per share. By that measure, the company beat the mean analyst estimate of $0.04. It beat the average revenue estimate of $120.75 million.

Quoting Management: “We were able to offset some of the revenue decline by successfully capturing sales and segment share with our non-AB rated oxymorphone hydrochloride extended-release products during our 180-day exclusivity period that expired in early July of this year,” said Larry Hsu, Ph.D., president and CEO, Impax Laboratories, Inc. “However, until we are able to close out the warning letter at our Hayward facility, we expect continued delays in receiving approval for a number of products pending at the FDA that could drive future growth. The absence of new product approvals, combined with additional generic competition and significant segment erosion of Zomig’s two largest dosage forms, will likely result in operating losses in the second half of this year.”

Key Stats (on next page)…

Revenue decreased 12.72% from $148.49 million in the previous quarter. EPS decreased 37.84% from $0.37 in the previous quarter.

Looking Forward: Analysts have a more negative outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has fallen from a loss of $0.05 to a loss $0.09. For the current year, the average estimate has moved down from a profit of $0.26 to a profit of $0.21 over the last ninety days.

Stocks with improving earnings metrics are worthy of your extra attention. In fact, “E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our CHEAT SHEET investing framework for this very reason. Don’t waste another minute – click here and get our CHEAT SHEET stock picks now.

(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at] wallstcheatsheet.com)